Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurora Cannabis ( (TSE:ACB) ) has provided an announcement.
Aurora Cannabis announced its fiscal first quarter 2026 results, highlighting a 37% increase in global medical cannabis net revenue to $64.8 million, with international revenue growing by 85%. The company achieved a 209% growth in adjusted EBITDA to $10.8 million and generated positive free cash flow of $9.2 million. Despite a decrease in consumer cannabis revenue, Aurora maintained a strong balance sheet with $186 million in cash and a debt-free cannabis business. The results underscore Aurora’s strategic focus on high-margin medical cannabis markets, particularly in Europe, and the continued expansion of its plant propagation business.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
Aurora Cannabis shows promising international growth and improved financial metrics, driven by a strategic focus on high-margin medical cannabis. However, challenges such as high valuation, inconsistent revenue, and cash flow issues weigh down the overall score.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc. is a leading global medical cannabis company based in Canada, focusing on the production and distribution of medical cannabis products. The company also operates a plant propagation business, diversifying its revenue streams beyond cannabis.
Average Trading Volume: 464,144
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$347M
See more insights into ACB stock on TipRanks’ Stock Analysis page.